This article was originally published in The Gray Sheet
Executive SummaryMajority-owned subsidiary of Acacia Research registers with the Securities and Exchange Commission for an initial public offering to support development of technology for production of customizable biological array processors. The semiconductor-based devices are used in identifying and determining the roles of genes, gene mutations and proteins as a tool in drug discovery and development. Acacia owns 58.3% of CombiMatrix and will retain its majority interest after the IPO. Salomon Smith Barney and J.P. Morgan are lead manager and co-manager, respectively, for the offering
You may also be interested in...
Aetion is also working with the US Food and Drug Administration and a number of biopharma companies on projects involving use of real-world evidence.